BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goh J, Godson C, Brady HR, Macmathuna P. Lipoxins: Pro-resolution lipid mediators in intestinal inflammation. Gastroenterology 2003;124:1043-54. [DOI: 10.1053/gast.2003.50154] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Morgan MD, Harper L, Lu X, Nash G, Williams J, Savage COS. Can neutrophils be manipulated in vivo? Rheumatology 2005;44:597-601. [DOI: 10.1093/rheumatology/keh507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
2 Louw JA, Marks IN. The management of peptic ulcer disease. Curr Opin Gastroenterol 2003;19:533-9. [PMID: 15703601 DOI: 10.1097/00001574-200311000-00004] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
3 Liu H, Zeng J, Huang W, Xu Q, Ye D, Sun R, Zhang D. Colorectal Cancer Is Associated with a Deficiency of Lipoxin A4, an Endogenous Anti-inflammatory Mediator. J Cancer 2019;10:4719-30. [PMID: 31528237 DOI: 10.7150/jca.32456] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
4 Malam Z, Marshall JC. The Neutrophil in the Pathogenesis of Multiple Organ Dysfunction Syndrome. In: Abraham E, Singer M, editors. Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Springer Berlin Heidelberg; 2007. pp. 183-201. [DOI: 10.1007/3-540-30328-6_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL, Merched A, Petasis NA, Chan L, Van Dyke TE. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003;171:6856-65. [PMID: 14662892 DOI: 10.4049/jimmunol.171.12.6856] [Cited by in Crossref: 289] [Cited by in F6Publishing: 271] [Article Influence: 16.1] [Reference Citation Analysis]
6 Shores DR, Binion DG, Freeman BA, Baker PR. New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis 2011;17:2192-204. [PMID: 21910181 DOI: 10.1002/ibd.21560] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
7 Leblanc R, Houssin A, Peyruchaud O. Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis. Br J Pharmacol 2018;175:3100-10. [PMID: 29777586 DOI: 10.1111/bph.14362] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
8 Ungaro F, D'Alessio S, Danese S. The Role of Pro-Resolving Lipid Mediators in Colorectal Cancer-Associated Inflammation: Implications for Therapeutic Strategies. Cancers (Basel) 2020;12:E2060. [PMID: 32722560 DOI: 10.3390/cancers12082060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Aliberti J, Bafica A. Anti-inflammatory pathways as a host evasion mechanism for pathogens. Prostaglandins, Leukotrienes and Essential Fatty Acids 2005;73:283-8. [DOI: 10.1016/j.plefa.2005.05.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao H, Li Y. Cancer metabolism and intervention therapy. Mol Biomed 2021;2:5. [PMID: 35006438 DOI: 10.1186/s43556-020-00012-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tabas I. Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis: The Importance of Lesion Stage and Phagocytic Efficiency. ATVB 2005;25:2255-64. [DOI: 10.1161/01.atv.0000184783.04864.9f] [Cited by in Crossref: 479] [Cited by in F6Publishing: 257] [Article Influence: 28.2] [Reference Citation Analysis]
12 Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 2004;101:15178-83. [PMID: 15471991 DOI: 10.1073/pnas.0405445101] [Cited by in Crossref: 175] [Cited by in F6Publishing: 160] [Article Influence: 9.7] [Reference Citation Analysis]
13 Futokoro R, Hijioka M, Arata M, Kitamura Y. Lipoxin A4 Receptor Stimulation Attenuates Neuroinflammation in a Mouse Model of Intracerebral Hemorrhage. Brain Sciences 2022;12:162. [DOI: 10.3390/brainsci12020162] [Reference Citation Analysis]
14 Ungaro F, Rubbino F, Danese S, D'Alessio S. Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases. Front Immunol 2017;8:1331. [PMID: 29109724 DOI: 10.3389/fimmu.2017.01331] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
15 Goh KL, Quek KF, Yeo GT, Hilmi IN, Lee CK, Hasnida N, Aznan M, Kwan KL, Ong KT. Colorectal cancer in Asians: a demographic and anatomic survey in Malaysian patients undergoing colonoscopy. Aliment Pharmacol Ther. 2005;22:859-864. [PMID: 16225496 DOI: 10.1111/j.1365-2036.2005.02646.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
16 Laskin D, Gardner C, Laskin J. Phagocytes. Comprehensive Toxicology. Elsevier; 2010. pp. 133-53. [DOI: 10.1016/b978-0-08-046884-6.00607-2] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
17 Serhan CN. A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution. Histochem Cell Biol 2004;122:305-21. [PMID: 15322859 DOI: 10.1007/s00418-004-0695-8] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 6.1] [Reference Citation Analysis]
18 Baumgartner HK, Starodub OT, Joehl JS, Tackett L, Montrose MH. Cyclooxygenase 1 is required for pH control at the mouse gastric surface. Gut 2004;53:1751-7. [PMID: 15542509 DOI: 10.1136/gut.2004.040238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
19 Wawrzyniak P, Noureddine N, Wawrzyniak M, Lucchinetti E, Krämer SD, Rogler G, Zaugg M, Hersberger M. Nutritional Lipids and Mucosal Inflammation. Mol Nutr Food Res 2021;65:e1901269. [PMID: 32780927 DOI: 10.1002/mnfr.201901269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Serhan CN. Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases? Expert Opinion on Therapeutic Targets 2005;8:643-52. [DOI: 10.1517/14728222.8.6.643] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
21 Machado FS, Johndrow JE, Esper L, Dias A, Bafica A, Serhan CN, Aliberti J. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med. 2006;12:330-334. [PMID: 16415877 DOI: 10.1038/nm1355] [Cited by in Crossref: 207] [Cited by in F6Publishing: 199] [Article Influence: 12.9] [Reference Citation Analysis]
22 Mangino MJ, Brounts L, Harms B, Heise C. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006;79:84-92. [PMID: 16516812 DOI: 10.1016/j.prostaglandins.2005.10.004] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.9] [Reference Citation Analysis]
23 Merched AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008;22:3595-606. [PMID: 18559988 DOI: 10.1096/fj.08-112201] [Cited by in Crossref: 296] [Cited by in F6Publishing: 276] [Article Influence: 21.1] [Reference Citation Analysis]
24 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
25 Mckay DM, Macnaughton WK. Mechanisms and Consequences of Intestinal Inflammation. Physiology of the Gastrointestinal Tract. Elsevier; 2012. pp. 2075-99. [DOI: 10.1016/b978-0-12-382026-6.00078-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Kühn H, Römisch I, Belkner J. The role of lipoxygenase-isoforms in atherogenesis. Mol Nutr Food Res 2005;49:1014-29. [DOI: 10.1002/mnfr.200500131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
27 Kikut J, Mokrzycka M, Drozd A, Grzybowska-chlebowczyk U, Ziętek M, Szczuko M. Involvement of Proinflammatory Arachidonic Acid (ARA) Derivatives in Crohn’s Disease (CD) and Ulcerative Colitis (UC). JCM 2022;11:1861. [DOI: 10.3390/jcm11071861] [Reference Citation Analysis]
28 Hasturk H, Schulte F, Martins M, Sherzai H, Floros C, Cugini M, Chiu CJ, Hardt M, Van Dyke T. Safety and Preliminary Efficacy of a Novel Host-Modulatory Therapy for Reducing Gingival Inflammation. Front Immunol 2021;12:704163. [PMID: 34589083 DOI: 10.3389/fimmu.2021.704163] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Aliberti J. Host persistence: exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol 2005;5:162-70. [PMID: 15662369 DOI: 10.1038/nri1547] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 5.4] [Reference Citation Analysis]
30 Rogler G. Resolution of inflammation in inflammatory bowel disease. Lancet Gastroenterol Hepatol 2017;2:521-30. [PMID: 28606878 DOI: 10.1016/S2468-1253(17)30031-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
31 Weinberger B, Quizon C, Vetrano AM, Archer F, Laskin JD, Laskin DL. Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4. Pediatr Res 2008;64:393-8. [PMID: 18535486 DOI: 10.1203/PDR.0b013e318180e4af] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
32 Sato Y, Kitasato H, Murakami Y, Hashimoto A, Endo H, Kondo H, Inoue M, Hayashi I. Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo. Biomedicine & Pharmacotherapy 2004;58:381-7. [DOI: 10.1016/j.biopha.2004.05.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
33 Souza DG, Fagundes CT, Amaral FA, Cisalpino D, Sousa LP, Vieira AT, Pinho V, Nicoli JR, Vieira LQ, Fierro IM, Teixeira MM. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007;179:8533-43. [PMID: 18056401 DOI: 10.4049/jimmunol.179.12.8533] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 7.1] [Reference Citation Analysis]
34 Machado FS, Aliberti J. Role of lipoxin in the modulation of immune response during infection. Int Immunopharmacol 2008;8:1316-9. [PMID: 18687293 DOI: 10.1016/j.intimp.2008.01.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]